Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Gp120

Vaccine · Immune activation, directed at HIV envelope glycoprotein gp120

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Gp120?

Gp120 is an HIV envelope glycoprotein antigen, given with a viral vector (MVA) dose by intramuscular or subcutaneous injection. It is studied in HIV infections.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Targets
HIV envelope glycoprotein gp120 (antigen)
Mechanism
Immune activation, directed at HIV envelope glycoprotein gp120
Therapy area
Infectious disease
In trials of
GOVX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
F2L0YR2AFI

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04041674 Phase 1 HIV Infections Withdrawn GOVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV Infections

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.